Zacks Investment Research
02 Feb 2026, 16:00 UTC · 40w ago
Verdict
Headline leans bullish. We score IBIO +0.20 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.20slightly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish
iBio's quarterly revenues are expected to be $0.1 million, down 50% from the year-ago quarter.
So whatA halving of revenue is a substantial top-line deterioration that poses a significant negative risk to the company's valuation and financial viability.
More negative than 88% of claims this week
iBio, Inc. is expected to report a quarterly loss of $0.08 per share, reflecting a year-over-year earnings improvement of 83.3%.
Continue reading
5 related stories
More positive than 56% of ticker scores this week
Scored by the NIS engine · methodology.
More positive than 63% of claims this week
The consensus EPS estimate for iBio has been revised 3.45% higher over the last 30 days.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 56% of ticker scores this week
The company is expected to show a year-over-year increase in earnings and has seen a slight upward revision in consensus EPS estimates.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
29m ago
−60.8%
Price is moving against the score
$0.8242 vs $2.10 close before publication (Jan 30) · not market-adjusted
IBIO chart →
